A comparison of the efficacy and tolerability of the PCSK9 inhibitors, Alirocumab and evolocumab, in routine lipid clinic practice

2017 ◽  
Vol 263 ◽  
pp. e247
Author(s):  
Alan Jones ◽  
Kate Peers ◽  
Sud Ramachandran ◽  
Ateeq Syed
Keyword(s):  
Pcsk9 Inhibitors ◽  
Lipid Clinic ◽  
Clinic Practice

Early Experience With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors In Patients Treated In An Outpatient Lipid Clinic

2016 ◽  
Vol 10 (3) ◽  
pp. 716
Author(s):  
Andrea Hirsch ◽  
Kelly Bartsch ◽  
Melissa Snider ◽  
John Larry ◽  
Stacy Morton ◽  
...  
Keyword(s):  
Early Experience ◽  
Proprotein Convertase ◽  
Pcsk9 Inhibitors ◽  
Lipid Clinic

scholarly journals Effectiveness and Tolerability of Alternative Statin Dosing in Daily Statin Intolerant Patients in the Era of PCSK9 Inhibitors

2020 ◽  
pp. 1-4
Author(s):  
Anthony P. Morise ◽  
Anthony P. Morise ◽  
Jennifer A. Tennant
Keyword(s):  
Cardiovascular Disease ◽  
Baseline Level ◽  
Ldl Cholesterol ◽  
Atherosclerotic Cardiovascular Disease ◽  
Pcsk9 Inhibitors ◽  
Statin Intolerance ◽  
Lipid Clinic ◽  
Cholesterol Goal ◽  
Pcsk9 Inhibition ◽  
Clinic Population

Background: Intolerance to the daily use of statins can be dealt with by the use of Proprotein Catylase Subtilisin Kexin Type 9 (PCSK9) inhibitors. Alternative statin dosing has previously been utilized in patients with statin intolerance. Methods: Since the introduction of PCSK9 inhibitors for clinical use in 2015, we evaluated the effectiveness of alternative statin dosing in patients with daily statin intolerance defined as the inability to tolerate the daily use of any dose of statin. Alternative statin dosing was defined as weekly, twice weekly, or every other day atorvastatin or rosuvastatin. From our lipid clinic population of 505 patients with primary hypercholesterolemia (71% with atherosclerotic cardiovascular disease), 338 (67%) had daily statin intolerance. Alternative statin dosing was agreed to by 122 patients of these 338. At the time of this analysis, 87 patients (59% with atherosclerotic cardiovascular disease) could be assessed concerning the effectiveness of alternative statin dosing to achieve their LDL-cholesterol goal. Results: Of the 87 patients undergoing alternative statin dosing with or without ezetimibe, 30 (34%) achieved their goal. An additional 22 patients had a >30% reduction in LDL-cholesterol with oral therapy alone. Twenty-nine of the 87 patients later received PCSK9 inhibition with 27 achieving either their goal or a >30% reduction in LDL cholesterol. The baseline LDL-cholesterol of those achieving their goal LDLcholesterol with alternative statin dosing (154 + 40 mg/dL) could not be distinguished (p=0.79) from those who later required PCSK9 inhibition to achieve their goal (157 + 41 mg/dL). Intolerance to alternative statin dosing was seen in 24 of the 87 (28%) patients. Conclusion: In conclusion, prior to initiating PCSK9 inhibition in patients with daily statin intolerance, a trial of alternative statin dosing should be attempted. The success of alternative statin dosing cannot be predicted by the baseline level of LDL-cholesterol.

Efficacy And Safety Of Pcsk9 Inhibitors: The Real-Life Experience Of The Lipid Clinic In Modena, Italy

2019 ◽  
Vol 287 ◽  
pp. e200
Author(s):  
S. Lugari ◽  
F. Nascimbeni ◽  
A. Mondelli ◽  
S. Bursi ◽  
G. Onfiani ◽  
...  
Keyword(s):  
Life Experience ◽  
Real Life ◽  
Efficacy And Safety ◽  
Pcsk9 Inhibitors ◽  
The Real ◽  
Lipid Clinic

scholarly journals PCSK9 Inhibitors in a Statin-Intolerant Transgender Man With Heterozygous Familial Hypercholesterolemia: A Case Report

2019 ◽  
Vol 3 (8) ◽  
pp. 1461-1464 ◽  
Author(s):  
Carlo Pirazzi ◽  
Federica Tavaglione ◽  
Åsa Tivesten ◽  
Stefano Romeo
Keyword(s):  
Familial Hypercholesterolemia ◽  
Low Density Lipoprotein ◽  
Genetic Diagnosis ◽  
Density Lipoprotein ◽  
Statin Treatment ◽  
Lipoprotein Cholesterol ◽  
Pcsk9 Inhibitors ◽  
Pcsk9 Inhibitor ◽  
Lipid Clinic ◽  
High Doses

Abstract In female-to-male transgender individuals, testosterone is used to induce masculinization. Sex steroid therapy may increase circulating triglyceride and low-density lipoprotein cholesterol (LDL-C) levels and may decrease high-density lipoprotein cholesterol (HDL-C) levels, resulting in a more atherogenic lipid profile. These potentially adverse effects of androgen therapy may be exacerbated by the presence of familial hypercholesterolemia (FH). We describe the case of a transgender man with genetically diagnosed FH who was intolerant to statins and was started on a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to control his lipoproteins more effectively. The 35-year-old female-to-male transgender individual was referred to our center with a history of elevated LDL-C levels. Despite treatment with high doses of high-potency statins and ezetimibe, he had never achieved a sustained reduction in LDL-C; his levels of LDL-C were fluctuating between 170 and 344 mg/dL (4.4 and 8.9 mmol/L). Moreover, he developed side effects to statins in the form of myalgia and discontinued statin treatment. At the Sahlgrenska Lipid Clinic, a genetic diagnosis of heterozygous FH was established, and PCSK9 inhibitor therapy was started. The patient’s LDL-C level has been reduced by approximately 40% for 23 months, and no adverse events have been reported.

PCSK9 inhibitors: The breakthrough lipid-lowering treatment at real-life setting. A 2-year regional lipid clinic experience

2020 ◽  
Vol 315 ◽  
pp. e257-e258
Author(s):  
G. Anastasiou ◽  
G. Liamis ◽  
H. Milionis ◽  
M. Elisaf ◽  
E. Christopoulou ◽  
...  
Keyword(s):  
Real Life ◽  
Lipid Lowering ◽  
Pcsk9 Inhibitors ◽  
Lipid Clinic ◽  
Real Life Setting ◽  
Clinic Experience

Evaluation of the Use of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Statin Intolerant Patients of an Outpatient Lipid Clinic

2017 ◽  
Vol 11 (3) ◽  
pp. 822-823
Author(s):  
Erica Davidson ◽  
Melissa Snider ◽  
Kelly Bartsch ◽  
Andrea Hirsch ◽  
John Larry
Keyword(s):  
Proprotein Convertase ◽  
Pcsk9 Inhibitors ◽  
Lipid Clinic

PCSK9 inhibitors: The breakthrough lipid-lowering treatment at real-life setting. A 3-year regional lipid clinic experience

2021 ◽  
Vol 331 ◽  
pp. e134
Author(s):  
G. Anastasiou ◽  
G. Liamis ◽  
H. Milionis ◽  
M. Elisaf ◽  
E. Christopoulou ◽  
...  
Keyword(s):  
Real Life ◽  
Lipid Lowering ◽  
Pcsk9 Inhibitors ◽  
Lipid Clinic ◽  
Real Life Setting ◽  
Clinic Experience

scholarly journals PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients

2020 ◽  
Vol 5 (1) ◽  
Author(s):  
José Juan Ceballos-Macías ◽  
Carolina Lara-Sánchez ◽  
Jorge Flores-Real ◽  
Carlos Alberto Aguilar-Salinas ◽  
Guillermo Ortega-Gutiérrez ◽  
...  
Keyword(s):  
Real World ◽  
Standard Therapy ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipid Lowering ◽  
Low Density Lipoprotein Cholesterol ◽  
Pcsk9 Inhibitors ◽  
Lipid Clinic ◽  
Real World Setting ◽  
Lipid Lowering Effect

Abstract A real-world setting study of familial hypercholesterolemia (FH) patients who received Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in a specialized referral center in Mexico City. Ten patients between the ages of 18 and 70 years, with a diagnosis of FH according to Dutch Lipid Clinic Network (DLCN) criteria, with failure to achieve their Low-density lipoprotein Cholesterol (LDL-C) goals, and with standard therapy between 2016 and 2017 enrolled in a simple randomization in which a group of 5 participants received alirocumab (75 mg every 2 weeks) and the remaining 5 patients received evolocumab (140 mg every 2 weeks). Comparative analysis was made, analyzing the means of LDL at baseline at 4, 6, and 12 weeks. The evolocumab group had an average initial LDL-C of 277 mg/dL, which, after 12 weeks of treatment, was significantly reduced to 116 mg/dL; P = 0.04 (95% confidence interval [CI]: 11.5–310.9). The alirocumab group with a mean initial LDL-C of 229 mg/dL showed a reduction of LDL-C levels at 12 weeks of treatment to 80 mg/dL; P = 0.008 (95% CI: 63.8–233.7). In conclusion, PCSK9 inhibitors are an excellent treatment option in patients with FH who do not reach their LDL-C goals with standard therapy or due to intolerance to the standard therapy. There is no difference in the lipid-lowering effect between both PSCK9 inhibitors.

Impact of PCSK9 Inhibitors on hypercholesterolaemic patients at a tertiary centre lipid clinic

2021 ◽  
Author(s):  
Alisha Israni ◽  
Ben Jones ◽  
Victoria Salem ◽  
Vassiliki Bravis
Keyword(s):  
Pcsk9 Inhibitors ◽  
Lipid Clinic ◽  
Tertiary Centre
Sign in / Sign up

Export Citation Format

Share Document